Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01269723 · ClinicalTrials.gov registry record · NA

Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers

A NA study of Smoking, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
51
Enrollment target
1
Study location

NCT01269723: Completed NA study of Smoking, sponsored by University of North Carolina, Chapel Hill.

NCT01269723 is a NA study of Smoking that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 51 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01269723, a NA study of Smoking, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

Vegetables such as broccoli, cauliflower, kale and cabbage are particularly rich in a plant chemical called sulforaphane (SFN) which boosts production of certain "defense" enzymes that increase the activity of antioxidants. In animals, the chemical protection from SFN helps prevent diseases associated with inflammation and cancer among others, and this is currently being studied in humans. Young broccoli sprouts have a particularly high level of SFN compared to other foods. The purpose of this research study is to learn about short term responses to live attenuated influenza virus (LAIV, administered to you via Flumist® vaccine) between smoking and nonsmoking volunteers treated with broccoli sprout homogenates ("shake") or a placebo homogenate. This will be done by obtaining a series of "nasal lavages" or rinses of your nose with salt water, as well as 3 superficial biopsies of the inside lining of your nose both before and after you receive the vaccine. Using these samples, we will measure the amount of virus and the amount of inflammation in your nose and compare how smokers and nonsmokers respond to the vaccine when they are given a broccoli sprout homogenate (high in SFN) or a placebo alfalfa spout "shake" which is low in SFN during each of 4 study visits. Subjects will be seen for a screening visit (inc. HIV test) and then randomly assigned to receive 1 of 2 homogenates. Broccoli sprout homogenate will be the the active treatment arm while the placebo arm will be alfalfa sprout homogenate. Two to 4 weeks after screening, subjects will return for 5 sequential visits (Monday-Friday). Monday-Thursday they will receive the assigned homogenate. On Tuesday, they will receive the Flumist®vaccine. Subjects will also be seen at 1 and 3 weeks post vaccine. Nasal lavage (NL), blood samples and nasal biopsies will performed prior to and after study interventions.

Primary Outcome

This will be performed by repetitive spraying of sterile normal saline irrigation solution (5 ml total) into the nostril, followed by voluntary expelling of fluid by the subject into a specimen collection cup. Both nostrils are lavaged in this way and the resulting nasal lavage fluid (NLF) from both sides is combined.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Broccoli sprout homogenate
  • DIETARY_SUPPLEMENT Alfalfa sprout homogenate

Study Locations (1)

North Carolina

  • UNC Center for Environmental Medicine, Asthma and Lung Biology - Chapel Hill

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2010-12
Est. Completion 2013-03
Phase NA

What the finished NCT01269723 record still lists

NCT01269723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Broccoli sprout homogenate is the first listed.

NCT01269723 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT01269723 about?

NCT01269723 is a clinical study titled "Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers". Vegetables such as broccoli, cauliflower, kale and cabbage are particularly rich in a plant chemical called sulforaphane (SFN) which boosts production of certain "defense" enzymes that increase the activity of antioxidants. In animals, the chemical protection from SFN helps prevent diseases associat...

What is the current status of trial NCT01269723?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2010-12. Estimated completion is 2013-03.

What conditions does trial NCT01269723 study?

This clinical trial studies the following conditions: Smoking.

What interventions are being tested in trial NCT01269723?

The interventions under investigation include: Broccoli sprout homogenate (DIETARY_SUPPLEMENT), Alfalfa sprout homogenate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01269723?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01269723 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01269723's enrollment target sits among peer trials

51 94th of 123 higher than 30 of 123 other Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01269723, the US trial registry maintained by the National Library of Medicine. NCT01269723 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.